In our study, we found that CDK6-AS1 may serve as an independent poor prognostic biomarker candidate in gastric cancer, with a positive correlation to its target gene, CDK6. The low-CDK6-AS1 expression group showed more frequently mutated driver genes than the high-expression group. This evidence concerns the gene CDK6 and gastric cancer.